Treatment for Advanced Thyroid Cancer

FOR INFORMATION ON ADVANCED THYROID CANCER CLICK HERE

Do you have progressed or advanced thyroid cancer? Watch the trailer for ‘ Christine’s Story – living with advanced thyroid cancer

Watch Now
Get Your Copy

new dvd

Use of TKI drugs in the UK for advanced Thyroid Cancer

There are new anticancer drugs called ‘tyrosine kinase inhibitors’ (TKIs) which are becoming available for the targeted treatment of various types of advanced thyroid cancers. Examples include sorafenib and vandetanib.

In addition to this your doctor will talk to you about any available clinical trials that may be suitable for your situation. These aren’t always available in every cancer treatment centre so if there is a trial available it may involve referring you to another hospital for further discussion.

Sorafenib (Nexavar) has been approved for the treatment of locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer.
It is available in England via the Cancer Drugs Fund and in Scotland via the SMC

Vandetanib (Calpresa) has been approved for the treatment of progressive medullary thyroid cancer.
It is available in England via the Cancer Drugs Fund.

Cabozantinib (Cometriq) has been approved for the treatment of progressive medullary thyroid cancer.
It is available in England via the Cancer Drugs Fund.
It is also available to patients in Wales.

Lenvatinib (Lenvima) was licensed for use for patients with locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer in 2015.
It has not yet gained approval by the Cancer Drugs Fund and is available only via clinical trials.

UPDATE: 10th October 2016 the SMC has approved the use of Lenvima for differentiated thyroid cancer which means that patients in Scotland will be able to access the drug .Great news. BTCT had a role in making this happen via our comprehensive submission. Click here for more information.

Selunetemib will be available via clinical trials to some patients soon via clinical trials in the UK.[late 2016]
This TKI may encourage uptake of RAI again after patients have become non iodine avid. [no longer taking up RAI]

Watch Dr Kate Newbold presentation on the Updates on Treatment for Advanced Thyroid Cancer at the BTCT Patient / Doctor Forum December 2016

 

We are available on this number Monday to Friday from 10 am to 4 pm. Outside these times, please leave a message on our answer phone and we will get back to you as soon as we can.